A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Ontology highlight
ABSTRACT: Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and
SUBMITTER: Walker BA
PROVIDER: S-EPMC6326953 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA